These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31348813)

  • 21. Prevalence of and risk factors for HCV among incarcerated people at Great Tehran Prison: a cross-sectional study.
    SeyedAlinaghi S; Farhoudi B; Shahmohamadi E; Rasoolinejad M; Hasannezhad M; Rashidi MR; Dadras O; Moradi A; Parmoon Z; Ebrahimi H; Asadollahi-Amin A
    Int J Prison Health; 2023 Nov; 19(4):536-544. PubMed ID: 36757302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing.
    Enkelmann J; Gassowski M; Nielsen S; Wenz B; Roß S; Marcus U; Bremer V; Zimmermann R;
    Harm Reduct J; 2020 Jan; 17(1):7. PubMed ID: 31924208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study.
    Schulte B; Schmidt CS; Strada L; Rosenkranz M; Schäfer I; Verthein U; Reimer J
    Clin Infect Dis; 2020 May; 70(10):2199-2205. PubMed ID: 31631215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
    Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P
    Hepatology; 2021 Nov; 74(5):2366-2379. PubMed ID: 34105797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
    Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ;
    J Viral Hepat; 2024 Jan; 31(1):21-34. PubMed ID: 37936544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective study of hepatitis C incidence in Australian prisoners.
    Luciani F; Bretaña NA; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR;
    Addiction; 2014 Oct; 109(10):1695-706. PubMed ID: 24916002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting.
    Lafferty L; Rance J; Treloar C
    Drug Alcohol Depend; 2018 Feb; 183():96-101. PubMed ID: 29245104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and incidence of bloodborne viral infections among Danish prisoners.
    Christensen PB; Krarup HB; Niesters HG; Norder H; Georgsen J
    Eur J Epidemiol; 2000; 16(11):1043-9. PubMed ID: 11421474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus seroprevalence among patients enrolled at the opioid substitution therapy center in Bihar: A cross-sectional study.
    Kumar A; Mahajan H; Chaturvedi S; Kumar A; Kumar S; Sahoo GC; Das VNR; Pandey K
    PLoS One; 2023; 18(6):e0287333. PubMed ID: 37319276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
    Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
    BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
    Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
    Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incident hepatitis B virus infection and immunisation uptake in Australian prison inmates.
    Li H; Cameron B; Douglas D; Stapleton S; Cheguelman G; Butler T; Luciani F; Lloyd AR
    Vaccine; 2020 Apr; 38(16):3255-3260. PubMed ID: 32151462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy.
    Skipper C; Guy JM; Parkes J; Roderick P; Rosenberg WM
    Gut; 2003 Oct; 52(10):1500-4. PubMed ID: 12970145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seroprevalence of Hepatitis C Virus among Prisoners in Lakan Prison, North of Iran, Is There Still a Concern?
    Mohtasham-Amiri Z; Rezvani SM; Ashoori F; Behboodi M; Toosi H; Jafari-Shakib R
    Arch Iran Med; 2021 Oct; 24(10):765-770. PubMed ID: 34816699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey.
    Weild AR; Gill ON; Bennett D; Livingstone SJ; Parry JV; Curran L
    Commun Dis Public Health; 2000 Jun; 3(2):121-6. PubMed ID: 10902255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting.
    Hariri S; Sharafkhah M; Alavi M; Roshandel G; Fazel A; Amiriani T; Motamed-Gorji N; Bazazan A; Merat S; Poustchi H; Malekzadeh R
    Harm Reduct J; 2020 Aug; 17(1):56. PubMed ID: 32795371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C testing and status among opioid substitution treatment clients in New South Wales.
    Shand FL; Day C; Rawlinson W; Degenhardt L; Martin NG; Nelson EC
    Aust N Z J Public Health; 2014 Apr; 38(2):160-4. PubMed ID: 24690055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
    Morey S; Hamoodi A; Jones D; Young T; Thompson C; Dhuny J; Buchanan E; Miller C; Hewett M; Valappil M; Hunter E; McPherson S
    J Viral Hepat; 2019 Jan; 26(1):101-108. PubMed ID: 30315691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons.
    Macalino GE; Vlahov D; Sanford-Colby S; Patel S; Sabin K; Salas C; Rich JD
    Am J Public Health; 2004 Jul; 94(7):1218-23. PubMed ID: 15226146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.